Comparative Pharmacology
Head-to-head clinical analysis: LEVAQUIN versus LEVAQUIN IN DEXTROSE 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LEVAQUIN versus LEVAQUIN IN DEXTROSE 5 IN PLASTIC CONTAINER.
LEVAQUIN vs LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Levofloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, enzymes essential for DNA replication, transcription, repair, and recombination.
Levofloxacin is a fluoroquinolone antibacterial that inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, thereby inhibiting DNA replication and transcription.
LEVAQUIN (levofloxacin) 500 mg orally or intravenously once daily for most infections; 750 mg orally or intravenously once daily for more severe infections or complicated urinary tract infections.
750 mg intravenously every 24 hours for 5 days. Alternatively, 500 mg intravenously every 24 hours for 7-14 days depending on infection.
None Documented
None Documented
Terminal elimination half-life is 6-8 hours in patients with normal renal function; prolonged to 48-108 hours in severe renal impairment (CrCl <20 mL/min).
Terminal elimination half-life is approximately 6-8 hours in patients with normal renal function (creatinine clearance >80 mL/min); prolonged in renal impairment (up to 30-50 hours in severe impairment).
Primarily renal excretion as unchanged drug (approximately 87% in urine); fecal excretion accounts for <5% as unchanged drug and metabolites; biliary excretion is minimal.
Primarily renal excretion as unchanged drug (approximately 87% within 48 hours); less than 4% as metabolites; biliary/fecal excretion accounts for <5%.
Category C
Category C
Antibiotic (Fluoroquinolone)
Antibiotic (Fluoroquinolone)